RET and lung cancer: In the pediatric patient population, LIBRETTO-121 (NCT03899792) is a phase 1/2 trial evaluating selpercatinib in patients with advanced solid tumors and primary CNS tumors, not including lung cancer, that harbors a RET alteration.